Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

BPIFB4 gene therapy could protect against heart aging

By Brian Buntz | January 23, 2023

Heart diagram

[Medical Illustrations by Patrick Lynch, generated for multimedia teaching projects by the Yale University School of Medicine, Center for Advanced Instructional Media, 1987-2000. Via WikiMedia Commons]

A recently published paper in Cardiovascular Research found that a gene frequently found in centenarians could safeguard heart functionality.

In a rodent model, a team of researchers found that the bactericidal/permeability-increasing fold-containing family-B member-4 gene (BPIFB4) gene protected against deterioration of heart function in middle-aged mice (14 months old).

The researchers, led by Professor Paolo Madeddu of the University of Bristol, found that delivery of the gene through an adeno-associated virus (AAV serotype 9) with a liver-specific promoter led to robust protection against cardiovascular disease in rodents.

The study focused on the cardiac index and vascular density.

The BPIFB4 gene, when administered to elderly mice (18 months old), reversed the decrease of heart performance by the equivalent of 10 years in humans.

The researchers found that older failing hearts were deficient in the BPIFB4 protein and had a corresponding scarcity in capillaries and surrounding pericytes, cells found along the walls of capillaries.

“Most [genetic] mutations are insignificant,” Madeddu said in a press release. “In a few cases, however, the mutation can make the gene function worse or better, like for the mutant anti-aging gene we have studied here on human cells and older mice.”

The researchers noted that long-lived individuals are more likely to carry the longevity-associated variant of the BPIFB4 gene, which expresses high levels of the BPIFB4 protein in the blood. In addition, the protein may have anti-inflammatory properties.

The researchers also tested the BPIFB4 gene in an in vitro study involving human cardiac cells.

“By adding the longevity gene/protein to the test tube, we observed a process of cardiac rejuvenation: the cardiac cells of elderly heart failure patients have resumed functioning properly, proving to be more efficient in building new blood vessels,” said Monica Cattaneo, a researcher of the MultiMedica Group in Milan, Italy, in a press release.

The BPIFB4 protein protects heart function and appears to also play a role in the immune response, helping clear bacteria and other pathogens from the bloodstream.

In 2020, a research paper published in the International Journal of Molecular Sciences concluded that BPIFB4 could help treat hypertension, atherosclerosis, diabetic cardiopathy and other conditions.

A 2019 paper published in European Heart Journal projected that the same gene could protect against chronic ischemia.


Filed Under: Cardiovascular
Tagged With: BPIFB4, heart
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

BMS
Label update broadens Camzyos reach in obstructive HCM, trims echo burden for stable patients
FDA logo
FDA drug approvals holding steady at 44 YTD in 2024
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
tirzepatide
Lilly, Novo Nordisk battle surge in copycat weight-loss drugs amid safety concerns
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE